



Dreamsickle Kids Foundation, Inc
6895 E. Lake Mead Blvd Ste.6 #204
Las Vegas, NV 89156
702-SCD-2286
www.dreamsicklekids.org

Dear Members of the Drug Use Review Board,

On behalf of Dreamsickle Kids Foundation, I am writing to express our strong support for the adoption of prior authorization criteria for the two newly FDA-approved therapies for Sickle Cell Disease (SCD), Lyfegenia and Casgevy. As the first SCD organization established in Nevada in 2018, Dreamsickle Kids Foundation has been at the forefront of advocating for better health outcomes and providing direct support to SCD families during some of the most challenging times.

The passage of Bill AB254 was a significant milestone for our community, spearheaded by our organization alongside other advocates within the Nevada SCD community. This legislation has been instrumental in making new therapies more accessible to patients in Nevada, reflecting the state's innovative approach to SCD support. We are grateful for these efforts and are hopeful that the adoption of prior authorization for Lyfegenia and Casgevy will further enable patients to access these potentially life-changing treatments.

These therapies represent a transformative advancement in the treatment of SCD, offering new hopes for improved quality of life, reduced pain episodes, and fewer hospitalizations. It is crucial that our Medicaid program aligns its authorization practices to ensure that eligible patients can access these treatments without undue delay.

We understand the challenges associated with the high costs of these therapies. However, by implementing prior authorization criteria based on robust clinical findings and establishing quantity limits consistent with published scientific evidence, we can ensure that these therapies are used appropriately and effectively, optimizing patient outcomes while managing costs.



Dreamsickle Kids Foundation, Inc
6895 E. Lake Mead Blvd Ste.6 #204
Las Vegas, NV 89156
702-SCD-2286
www.dreamsicklekids.org

Dreamsickle Kids Foundation is committed to continuing our advocacy for the SCD community and collaborating with state agencies to support the health needs of these patients. We urge the Nevada Department of Health and Human Services, Division of Health Care Financing and Policy, and the Drug Use Review Board to move forward with these necessary criteria to enhance access to these innovative therapies.

Thank you for considering our views on this critical matter. We look forward to further dialogue and are ready to assist in any way to support the implementation of these changes.

Warm regards,

Georgene' Glass

Georgene' Glass

Executive Director

Dreamsickle Kids Foundation, Inc

ginaglass@dreamsicklekids.org